Abstract
Many issues remain unresolved about antipsychotic drugs. Their therapeutic potency scales with affinity for dopamine D2 receptors, but there are indications that they act indirectly, with dopamine D1 receptors (and others) as possible ultimate targets. Classical neuroleptic drugs disinhibit striatal cholinergic interneurones and increase acetyl choline release. Their effects may then depend on stimulation of muscarinic receptors on principle striatal neurones (M4 receptors, with reduction of cAMP formation, for therapeutic effects; M1 receptors for motor side effects). Many psychotic patients do not benefit from neuroleptic drugs, or develop resistance to them during prolonged treatment, but respond well to clozapine. For patients who do respond, there is a wide ( > ten-fold) range in optimal doses. Refractoriness or low sensitivity to antipsychotic effects (and other pathologies) could then arise from low density of cholinergic interneurones. Clozapine probably owes its special actions to direct stimulation of M4 receptors, a mechanism available when indirect action is lost.
Keywords: Antipsychotic drugs, neuroleptic drugs, cholinergic interneurones, D1 receptors, D2 receptors, muscarinic M1 receptors, muscarinic M4 receptors, neuroleptic threshold, atypical antipsychotic agents
Current Neuropharmacology
Title: Mechanisms of Action of Antipsychotic Drugs of Different Classes, Refractoriness to Therapeutic Effects of Classical Neuroleptics, and Individual Variation in Sensitivity to their Actions: PART I
Volume: 7 Issue: 4
Author(s): R. Miller
Affiliation:
Keywords: Antipsychotic drugs, neuroleptic drugs, cholinergic interneurones, D1 receptors, D2 receptors, muscarinic M1 receptors, muscarinic M4 receptors, neuroleptic threshold, atypical antipsychotic agents
Abstract: Many issues remain unresolved about antipsychotic drugs. Their therapeutic potency scales with affinity for dopamine D2 receptors, but there are indications that they act indirectly, with dopamine D1 receptors (and others) as possible ultimate targets. Classical neuroleptic drugs disinhibit striatal cholinergic interneurones and increase acetyl choline release. Their effects may then depend on stimulation of muscarinic receptors on principle striatal neurones (M4 receptors, with reduction of cAMP formation, for therapeutic effects; M1 receptors for motor side effects). Many psychotic patients do not benefit from neuroleptic drugs, or develop resistance to them during prolonged treatment, but respond well to clozapine. For patients who do respond, there is a wide ( > ten-fold) range in optimal doses. Refractoriness or low sensitivity to antipsychotic effects (and other pathologies) could then arise from low density of cholinergic interneurones. Clozapine probably owes its special actions to direct stimulation of M4 receptors, a mechanism available when indirect action is lost.
Export Options
About this article
Cite this article as:
Miller R., Mechanisms of Action of Antipsychotic Drugs of Different Classes, Refractoriness to Therapeutic Effects of Classical Neuroleptics, and Individual Variation in Sensitivity to their Actions: PART I, Current Neuropharmacology 2009; 7 (4) . https://dx.doi.org/10.2174/157015909790031229
DOI https://dx.doi.org/10.2174/157015909790031229 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Kynurenic Acid Analogues in the Treatment of Migraine and Neurodegenerative Disorders: Preclinical Studies and Pharmaceutical Design
Current Pharmaceutical Design Nasal Polyposis: An Overview of Differential Diagnosis and Treatment
Recent Patents on Inflammation & Allergy Drug Discovery Adult Neurogenesis and Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Polyunsaturated Fatty Acids in Emerging Psychosis
Current Pharmaceutical Design Applications of Lentiviral Vectors for Biology and Gene Therapy of Neurological Disorders
Current Gene Therapy On the Diversity of Oxidative Bioactivation Reactions on Nitrogen- Containing Xenobiotics
Current Drug Metabolism L-DOPA and Serotonergic Neurons: Functional Implication and Therapeutic Perspectives in Parkinson's Disease
Central Nervous System Agents in Medicinal Chemistry Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson’s Disease: From Bench to Bedside
Current Neuropharmacology Functional Selectivity in Cannabinoid Signaling
Current Molecular Pharmacology Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson’s Disease and Huntington’s Disease: A Review
Current Neuropharmacology Efficacy and Adverse Effects of Venlafaxine in Children and Adolescents with ADHD: A Systematic Review of Non-controlled and Controlled Trials
Reviews on Recent Clinical Trials Risperidone Rechallenge for Marked Liver Function Test Abnormalities in an Autistic Child
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Therapeutic Value of Adeno Associated Virus as a Gene Therapy Vector for Parkinson's Disease – A Focused Review
Current Gene Therapy Induced Pluripotent Stem Cell-Based Studies of Parkinson's Disease: Challenges and Promises
CNS & Neurological Disorders - Drug Targets Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research
Current Drug Targets Is rTMS an Effective Therapeutic Strategy that Can Be Used to Treat Parkinson's Disease?
CNS & Neurological Disorders - Drug Targets Computational Study of Human Tyrosine Hydroxylase Mutants to Uphold [4-(Propan-2-yl) Phenyl]Carbamic Acid as a Potential Inhibitor
CNS & Neurological Disorders - Drug Targets Parallel Roles for Dopamine in Pathological Gambling and Psychostimulant Addiction
Current Drug Abuse Reviews Metabotropic Glutamate Receptors as Therapeutic Targets for Cognitive Disorders
Current Topics in Medicinal Chemistry The Surgical Management of Parkinson's Disease
CNS & Neurological Disorders - Drug Targets